<DOC>
	<DOCNO>NCT00080860</DOCNO>
	<brief_summary>RATIONALE : Sentinel lymph node biopsy gene expression profile primary breast tumor may help determine tumor cell spread axillary lymph node help doctor plan effective surgery breast cancer . PURPOSE : This clinical trial study well sentinel lymph node biopsy primary tumor gene expression profile work find lymph node metastasis woman receive neoadjuvant therapy stage II , stage III , stage IV breast cancer .</brief_summary>
	<brief_title>Sentinel Lymph Node Biopsy Primary Tumor Gene Expression Profiling Finding Axillary Lymph Node Metastases Women Who Have Received Neoadjuvant Therapy Stage II , Stage III , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy sentinel lymph node mapping assess axillary lymph node status neoadjuvant therapy woman stage II , III , IV breast cancer . - Correlate gene expression profile primary breast cancer axillary sentinel lymph node status patient . OUTLINE : This pilot study . After neoadjuvant chemotherapy , patient undergo sentinel lymph node ( SLN ) map comprise technetium Tc 99m sulfur colloid inject subareolar area identify SLN . Within 1-2 hour injection , patient undergo SLN biopsy follow immediately definitive local surgery comprise modify radical mastectomy breast segmentectomy axillary lymph node dissection . SLN axillary lymph node examine hematoxylin eosin ( H &amp; E ) stain presence absence metastasis . If lymph node negative tumor H &amp; E , lymph node analyze immunohistochemistry . The primary tumor analyze microarray analysis gene expression profile determination . Patients follow 2-3 week surgery . PROJECTED ACCRUAL : A total 60 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma breast Stage II , III , IV infiltrate disease Unilateral bilateral AND unifocal multifocal disease Received least 1 course prior preoperative therapy ( chemotherapy , hormonal therapy , and/or biologic therapy ) AND follow response : Clinical complete response , partial response , change , disease progression Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Over 18 Sex Female Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Hemoglobin &gt; 7.0 g/dL Platelet count &gt; 50,000/mm^3 WBC &gt; 2,000/mm^3 Hepatic PT PTT &lt; 1.5 time normal Renal Not specify Other Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics Radiotherapy No prior definitive breast radiotherapy target breast Surgery No prior axillary surgery side sentinel lymph node Other More 3 day since prior radionuclide scan ( e.g. , bone scan , positronemission tomography scan , MUGA scan )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>